Pharming Group

Pharming Group Book Value per Share

The Book Value per Share of Pharming Group (PHARM.AS) as of Nov 17, 2026 is 0.41 USD. In the previous year, Book Value per Share was 0.33 USD — a change of 24.95% (higher).

Book Value per Share

0.41USD

YoY

24.95%

Last updated:

Book Value per Share of Pharming Group is 2025 0.41 USD. Book Value per Share of Pharming Group was 2024 0.33 USD. It decreases by 24.95% higher compared to the previous year.

The Pharming Group Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2018
0.11 USD
Jan 1, 2019
0.17 USD
Jan 1, 2020
0.27 USD
Jan 1, 2021
0.29 USD
Jan 1, 2022
0.30 USD
Jan 1, 2023
0.30 USD
Jan 1, 2024
0.33 USD
Jan 1, 2025
0.41 USD
The Pharming Group Book Value per Share history
YEARBook Value per ShareYoY
0.41USD+24.95%
0.33USD+11.97%
0.30USD-3.22%
0.30USD+6.19%
0.29USD+4.89%
0.27USD+56.69%
0.17USD+66.00%
0.11USD+213.15%
0.03USD-21.91%
0.04USD+10.83%
0.04USD-28.18%
0.05USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pharming Group Stock analysis

What does Pharming Group do? Pharming Group NV was founded in 1988 and is headquartered in the Netherlands. The company specializes in the development and marketing of medical products for the treatment of rare diseases. Its business model is based on the discovery and development of recombinant proteins. These proteins are produced using genetic engineering techniques and serve as the foundation for the development of therapeutic products in various areas. The main focus of Pharming Group NV is the manufacturing and marketing of biopharmaceuticals. The company has a wide range of products used in the treatment of rare diseases, including C1-esterase inhibitor preparations used for acute attacks in hereditary angioedema. Another important product of Pharming Group NV is recombinant human lysozyme. It is used in the treatment of cystic fibrosis and has shown promising results as a therapeutic approach. Pharming Group NV also collaborates closely with various research and development organizations to develop new products and expand knowledge in the medical industry. The company has experienced impressive growth in recent years. In 2019, Pharming Group NV achieved a revenue of 149 million euros. A significant portion of this revenue was generated through the sale of C1-esterase inhibitor preparations. Pharming Group NV has also made a name for itself in the international market. The company has branches in the USA and Europe and works closely with international regulatory authorities to ensure smooth approval and marketing of its products. Overall, Pharming Group NV has a promising future as it continues to invest in research, development, and expansion of its product portfolio. By focusing on the development of products for the treatment of rare diseases, Pharming Group NV positions itself as a leading company in the medical industry and contributes to improving the lives of people worldwide. Pharming Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pharming Group stock

Book Value per Share of Pharming Group is 0.41 USD in 2025.

Book Value per Share of Pharming Group changed from 0.33 USD to 0.41 USD, representing a 24.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share Pharming Group since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Pharming Group

All Key Metrics — Pharming Group